Fig. 1.
In case A, two metastatic lesions receive MDT at two different time-points. One would have to declare treatment failure at time-point t1, if the classical endpoint PFS were used, in contrast to using FLS, were the situation in case A would not be declared a failure. Case B is hardly oncologically different from A, and at t2, A and B might exhibit the same result.
